It seems blood tests for Aβ have moved off the wish list and are becoming reality—almost. Building a knowledge base for plasma measures as a proxy for brain amyloid, multiple methods applied to different research cohorts are now consistently linking low plasma Aβ42/40 to clinical, cognitive, and biomarker evidence of Alzheimer’s disease.
Blood Tests for Amyloid Step Out at CTAD
View Content